Antiproliferative effects of tyrosine kinase inhibitors (Tyrphostins) on human bladder and renal carcinoma cells

被引:16
作者
SionVardy, N
Vardy, D
Rodeck, U
Kari, C
Levin, RM
Malkowicz, SB
机构
[1] HOSP UNIV PENN,DEPT UROL,PHILADELPHIA,PA 19104
[2] WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104
关键词
D O I
10.1006/jsre.1995.1222
中图分类号
R61 [外科手术学];
学科分类号
摘要
Growth factor receptors with tyrosine kinase activity mediate paracrine and autocrine growth regulation of normal and malignant cells. The epidermal growth factor receptor (EG;F-R) is a tyrosine kinase transmembrane protein that is overexpressed by many epithelial malignancies, including transitional cell and renal cell carcinoma. Ligand-induced stimulation of cell growth depends on activation of the tyrosine kinase activity of the EGF-R. Tyrphostins are small molecular weight compounds that have been shown to preferentially inhibit the EGF-R tyrosine kinase and thus may inhibit EGF-R-dependent cell growth. We examined the effect of two tyrphostins, RG14620 and AG555, on the proliferation of three transitional cell carcinoma lines (RT4, 582, and T24) and three renal cell carcinoma lines (A-498, Caki-1, and Caki-2). Both tyrphostins inhibited proliferation of all six cell lines in a dose-dependent fashion. They were equally effective with IC(50)s ranging between 3 and 16 mu M. Complete inhibition of growth was achieved at tyrphostin concentrations between 10 and 30 mu M. Although both tyrphostins inhibited proliferation of T24 transitional carcinoma cells in growth assays, only RG14620 but not AG555 was found to specifically inhibit EGF-R autophosphorylation in this cell line. These results suggest that other intracellular targets in addition to the EGF-R are affected by these agents. In summary, tyrphostins are potent growth inhibitors for urological malignancies. (C) 1995 Academic Press, Inc.
引用
收藏
页码:675 / 680
页数:6
相关论文
共 23 条
[1]  
ATLAS I, 1992, CANCER RES, V52, P3335
[2]   EVALUATION OF EPIDERMAL GROWTH-FACTOR RECEPTORS IN BLADDER-TUMORS [J].
BERGER, MS ;
GREENFIELD, C ;
GULLICK, WJ ;
HALEY, J ;
DOWNWARD, J ;
NEAL, DE ;
HARRIS, AL ;
WATERFIELD, MD .
BRITISH JOURNAL OF CANCER, 1987, 56 (05) :533-537
[3]   TYRPHOSTINS .2. HETEROCYCLIC AND ALPHA-SUBSTITUTED BENZYLIDENEMALONONITRILE TYRPHOSTINS AS POTENT INHIBITORS OF EGF RECEPTOR AND ERBB2/NEU TYROSINE KINASES [J].
GAZIT, A ;
OSHEROV, N ;
POSNER, I ;
YAISH, P ;
PORADOSU, E ;
GILON, C ;
LEVITZKI, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (06) :1896-1907
[4]   TYROSINE PHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY OF THE TRK PROTOONCOGENE PRODUCT INDUCED BY NGF [J].
KAPLAN, DR ;
MARTINZANCA, D ;
PARADA, LF .
NATURE, 1991, 350 (6314) :158-160
[5]   EXPRESSION OF DIFFERENTIATION ANTIGENS AND GROWTH-RELATED GENES IN NORMAL KIDNEY, AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE, AND RENAL-CELL CARCINOMA [J].
KLINGEL, R ;
DIPPOLD, W ;
STORKEL, S ;
ZUMBUSCHENFELDE, KHM ;
KOHLER, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (01) :22-30
[6]   TYRPHOSTINS AS MOLECULAR TOOLS AND POTENTIAL ANTIPROLIFERATIVE DRUGS [J].
LEVITZKI, A ;
GILON, C .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1991, 12 (05) :171-174
[7]   EGF INDUCES TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-II - A POTENTIAL MECHANISM FOR EGF RECEPTOR SIGNALING [J].
MARGOLIS, B ;
RHEE, SG ;
FELDER, S ;
MERVIC, M ;
LYALL, R ;
LEVITZKI, A ;
ULLRICH, A ;
ZILBERSTEIN, A ;
SCHLESSINGER, J .
CELL, 1989, 57 (07) :1101-1107
[8]  
MESSING EM, 1990, CANCER RES, V50, P2530
[9]  
NEAL DE, 1990, CANCER, V65, P1619, DOI 10.1002/1097-0142(19900401)65:7<1619::AID-CNCR2820650728>3.0.CO
[10]  
2-Q